UDK: 615:611-013.1.2
L.I. Bugaeva, E.A. Kuzubova, M.V. Maltsev, E.B. Lavrova, I.N. Tyurenkov, D.V. Kurkin, E.V. Volotova, D.A. Bakulin, G.P. Dudchenko
ФГБОУ ВО «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации
In experiments on outbred male beauty 4 months of age, the effect of the new compound ZB-16 (GPR 119 receptor agonist), with hypoglycemic activity [6], on spermatogenesis and fertilizing function was studied. Compound ZB-16 was administered intragastrically to animals of the experimental groups for 2 months (equivalent to one spermatogenesis cycle) in doses: 0,5 mg/kg (experimental therapeutic dose) and 100 mg/kg (higher dose than 200 times the therapeutic dose), the control group of males was intragastrically injected with a solvent of the compound – distilled water. It was found that under the influence of ZB-16, in males in both experimental groups, the spermatogenesis index is moderately increased (by 3,0 %, p > 0,05), the total number of spermatozoa (by 44,4 %, p > 0,05 and 19,2 %, p > 0,05, respectively, the 1st and 2nd experimental groups), the number of tubules with desquamated epithelium decreases, and the number of pathological forms of spermatozoa and the number of tubules with 12th stage of meiosis are not changed. According to the results of mating of the studied groups of males with intact females, a clear tendency towards an increase in the pregnancy index and a decrease in the post-implantation death of the embryos is revealed in the females relative to the control.
hypoglycemic agents, GPR-119 receptor agonist, generative function, spermatogenesis, fertility.
Тюренков Иван Николаевич – член-корр. РАН, д. м. н., профессор, заведующий кафедрой фармакологии и биофармации Института НМФО, Волгоградский государственный медицинский университет, e-mail: fibfuv@mail.ru